Multiple Myeloma Coverage from Every Angle

Jiye Liu, PhD, on Clinical Implications of Findings on KDM6A as a Modulator of Daratumumab Sensitivity in Multiple Myeloma

Posted: Thursday, January 5, 2023

Jiye Liu, PhD, of Dana-Farber Cancer Institute, discusses research on identifying novel regulators mediating CD38 expression and daratumumab sensitivity in multiple myeloma and the use of a genome-wide CRISPR-Cas9 screen. The study led to the validation of combination treatment with an FDA-approved EZH2 inhibitor plus daratumumab, which can overcome daratumumab resistance in preclinical multiple myeloma models.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.